Sandoz : Pyzchiva Approved In Europe For Gastroenterology, Dermatology, And Rheumatology Treatments
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Pyzchiva (biosimilar ustekinumab), developed and registered by Samsung Bioepis.
Pyzchiva is approved as a biologic therapy within gastroenterology, dermatology, and rheumatology.
Pyzchiva is approved as a biologic therapy within gastroenterology, dermatology, and rheumatology.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1824226142-5daaa8e03e6e497a90c9658c943d8693.jpg "How Serial Entrepreneurs Are Reshaping Wealth Creation")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2058309470-c33b092093a4445098775c2b8bd538fe.jpg "Best Dividend Stocks for November 2024")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1451277892-5d6677cb7ffe42999ba03f993d1a1ba8.jpg "Are My Social Security Disability Benefits Taxable?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1358880761-82e600bfa20f4c2a8c48dc39cebeb0b0.jpg "<div>Accountant vs. Controller: What's the Difference?</div>")